What is AMGN's current stock price?

As of now, AMGN is trading at $313.85, with a daily change of -2.30%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

AMGN Stock Analysis & IQ Rating | Amgen

AMGN

Amgen

$313.85

-$7.38 | -2.30%

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$346.38

MKT CAP

$169.00B

52W Low

$253.3

VOL

$2.92M

P/E Ratio

44.81

AVG VOL

$2.93M

RSI

39.99

TREND

Sideways

AMGN Stock IQ

Login to see Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AMGN Target Price

Login to display

Strengths

AMGN Rewards

Earnings are forecast to grow

AMGN Rewards

Trading below its fair value

AMGN Rewards

Upgraded on attractively valued

AMGN Rewards

Outperform the market

Risk Analysis

AMGN Risk Analysis

Investors losing their confidence

AMGN Price Performance

$336.28 (-6.67%)

$273.08 (+14.93%)

$295.87 (+6.08%)

$264 (+18.88%)

1year

6month

3month

1month

AMGN Risk Level

AMGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AMGN Analysts Opinion

AMGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

AMGN Analysts Opinion

AMGN Analysts opinion is positive and also has improved from the past 3 months

AMGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

78%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

100%

AMGN Street Sentiment

AMGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AMGN Performance Sentiment

Sentiments overview associated with AMGN events and the stock performance.

78%

9%

Positive

Negative

18 out of 23
events present

2 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$321.23

Resistance
Price

$307.35

Current Price Range

$345.46

Show methods +

Linked to AMGN

IQ

Close Price

Change

MRNA

3.62

28.24

+0.97%

BIIB

4.24

175.84

-2.55%

EXEL

4.27

41.87

-0.71%

CRSP

3.92

57.04

-0.56%

CHRS

2.35

1.29

+0.78%

AMGN Latest Analysis +

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND. ) today announced that its Board of Directors declared a About Amgen Amgen discovers develops manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world'.s toughest diseases. More than 40 years ago Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation using technology and human genetic data to push beyond what'.s known today. Amgen is advanci

Today

$313.85 | -2.30%

Activity

Potential

Recent Filing Shows That Rep. David Taylor Sold Over $2K Worth of Amgen Stock. Records from December 5 2025 indicate that Representative David Taylor of Ohio made a sale of Amgen (NASDAQ:) valued between $2002 and $30000 with the transaction dated December 3 2025 and filed in December.As of now Amgen shares are trading down 1.25% at $325.76.In the last three years David Taylor completed 69 stock transactions totaling more than $97 thousand. UnitedHealth Group and Eli Lilly stocks were among the

Mon Dec 8, 2025

$321.23 | -2.63%

Activity

BMO Capital Maintains Amgen (AMGN) Outperform Recommendation. Fintel reports that on December 3 2025 BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform recommendation. Analyst Price Forecast Suggests 3.25% Downside

Thu Dec 4, 2025

$340.16 | -1.52%

Momentum

Potential

Rating

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript.

Wed Dec 3, 2025

$345.42 | +2.09%

Activity

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Wed Dec 3, 2025

$345.42 | +2.09%

Activity

Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts. Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the companys obesity medication MariTide which are anticipated by years end. Following previously disclosed induction results from Part [….]

Wed Dec 3, 2025

$345.42 | +2.09%

Rating

Noteworthy Monday Option Activity: AMGN NLY CRM. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN) where a total of 16674 contracts have traded so far representing approximately 1.7 million underlying shares. That amounts to about 54.6% of

Mon Dec 1, 2025

$337.49 | -2.31%

Momentum

AMGN Up Almost 16% in a Month: Should You Buy Sell or Hold the Stock?. Amgens nearly 16% surge follows strong Q3 results raised sales guidance and growing momentum across key drugs and biosimilars.

Mon Dec 1, 2025

$337.49 | -2.31%

Earnings

Potential

ARWR: Multiple Data Readouts Ahead in 2026. By Business UpdateMultiple Data Readouts Ahead in 2026Following the recent approval of REDEMPLO® for the treatment of patients with familial chylomicronemia syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week following approval which is ahead of schedule. While the company is focused on a successful commercial launch there are a number

Mon Dec 1, 2025

$337.49 | -2.31%

Activity

AMGEN TO PRESENT AT CITIS 2025 GLOBAL HEALTHCARE CONFERENCE. THOUSAND OAKS Calif. Nov. 24 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citis 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3 2025. Peter Griffith executive vice president and chief financial officer at Amgen and Jay Bradner executive vice president...

Mon Nov 24, 2025

$334.30 | -0.96%

Activity

FAQ About AMGN Stock Insights

What is AMGN current stock price?

What are AMGN stock strengths?

What is AMGN Risk Level?

What is AMGN market cap and volume?

What is AMGN current Stock IQ?

Should I buy AMGN stock right now?

Is AMGN a Strong Buy right now?

What does a 'Strong Buy' rating mean for AMGN?

What does a 'Strong Sell' rating mean for AMGN?

What factors influence AMGN's Stock IQ?

Explore our AMGN Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored AMGN Stock Strategies
Effective Risk Management

FIND US ON

Receive our AMGN Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

AMGN

Amgen

Current Price

$313.85

-$7.38 | -2.30%

52W High

$346.38

MKT CAP

$169.00B

52W Low

$253.3

VOL

$2.92M

P/E Ratio

44.81

AVG VOL

$2.93M

RSI

39.99

TREND

Sideways

Create Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

AMGN Rewards

Earnings are forecast to grow

AMGN Rewards

Trading below its fair value

AMGN Rewards

Upgraded on attractively valued

AMGN Rewards

Outperform the market

Risk Analysis

AMGN Risk Analysis

Investors losing their confidence

Linked to AMGN

Symbol

IQ

Close

Change

MRNA

3.62

28.24

+0.97%

BIIB

4.24

175.84

-2.55%

EXEL

4.27

41.87

-0.71%

CRSP

3.92

57.04

-0.56%

CHRS

2.35

1.29

+0.78%

AMGN Price Performance

$336.28 (-6.67%)

$273.08 (+14.93%)

$295.87 (+6.08%)

$264 (+18.88%)

1year

6month

3month

1month

AMGN Analysts Opinion

AMGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

AMGN Analysts Opinion

AMGN Analysts opinion is positive and also has improved from the past 3 months

AMGN Street Sentiment

Analysts perspectives on the stock desirability, trend direction, and growth potential

78%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

67%

100%

AMGN Street Sentiment

AMGN Street Sentiment is extremely bullish and have positive views on the near-term outlook

AMGN Risk Level

AMGN has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.

Click here to check what is your level of risk

Low

LOW

HIGH

AMGN Performance Sentiment

Sentiments overview associated with AMGN events and the stock performance.

78%

9%

Positive

Negative

18 out of 23
events present

2 out of 23
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Login to display

Support
Price

$321.23

Resistance
Price

$307.35

Current Price Range

$345.46

Show methods +

AMGN Stock IQ

Login to unlock Amgen (AMGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

AMGN Latest Analysis

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND. ) today announced that its Board of Directors declared a About Amgen Amgen discovers develops manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world'.s toughest diseases. More than 40 years ago Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation using technology and human genetic data to push beyond what'.s known today. Amgen is advanci

Today

$313.85 | -2.30%

Activity

Potential

Recent Filing Shows That Rep. David Taylor Sold Over $2K Worth of Amgen Stock. Records from December 5 2025 indicate that Representative David Taylor of Ohio made a sale of Amgen (NASDAQ:) valued between $2002 and $30000 with the transaction dated December 3 2025 and filed in December.As of now Amgen shares are trading down 1.25% at $325.76.In the last three years David Taylor completed 69 stock transactions totaling more than $97 thousand. UnitedHealth Group and Eli Lilly stocks were among the

Mon Dec 8, 2025

$321.23 | -2.63%

Activity

BMO Capital Maintains Amgen (AMGN) Outperform Recommendation. Fintel reports that on December 3 2025 BMO Capital maintained coverage of Amgen (NasdaqGS:AMGN) with a Outperform recommendation. Analyst Price Forecast Suggests 3.25% Downside

Thu Dec 4, 2025

$340.16 | -1.52%

Momentum

Potential

Rating

Amgen Inc. (AMGN) Presents at Evercore 8th Annual Healthcare Conference Transcript.

Wed Dec 3, 2025

$345.42 | +2.09%

Activity

Amgen Inc. (AMGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript.

Wed Dec 3, 2025

$345.42 | +2.09%

Activity

Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts. Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the companys obesity medication MariTide which are anticipated by years end. Following previously disclosed induction results from Part [….]

Wed Dec 3, 2025

$345.42 | +2.09%

Rating

Noteworthy Monday Option Activity: AMGN NLY CRM. Among the underlying components of the Russell 3000 index we saw noteworthy options trading volume today in Amgen Inc (Symbol: AMGN) where a total of 16674 contracts have traded so far representing approximately 1.7 million underlying shares. That amounts to about 54.6% of

Mon Dec 1, 2025

$337.49 | -2.31%

Momentum

AMGN Up Almost 16% in a Month: Should You Buy Sell or Hold the Stock?. Amgens nearly 16% surge follows strong Q3 results raised sales guidance and growing momentum across key drugs and biosimilars.

Mon Dec 1, 2025

$337.49 | -2.31%

Earnings

Potential

ARWR: Multiple Data Readouts Ahead in 2026. By Business UpdateMultiple Data Readouts Ahead in 2026Following the recent approval of REDEMPLO® for the treatment of patients with familial chylomicronemia syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is now a commercial-stage company and recently reported that the drug is available for patients only one week following approval which is ahead of schedule. While the company is focused on a successful commercial launch there are a number

Mon Dec 1, 2025

$337.49 | -2.31%

Activity

AMGEN TO PRESENT AT CITIS 2025 GLOBAL HEALTHCARE CONFERENCE. THOUSAND OAKS Calif. Nov. 24 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citis 2025 Global Healthcare Conference at 1:45 p.m. ET on December 3 2025. Peter Griffith executive vice president and chief financial officer at Amgen and Jay Bradner executive vice president...

Mon Nov 24, 2025

$334.30 | -0.96%

Activity

Discover AMGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AMGN. We're here to help you make informed investment decisions today.

FIND US ON

Receive our AMGN Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

AMGN Stock trends

AMGN Stock performance

AMGN Stock analysis

AMGN investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AMGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing AMGN

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

AMGN Stock Analysis & IQ Rating | Amgen

AMGN Stock IQ

AMGN Target Price

AMGN Risk Level

AMGN Analysts Opinion

AMGN Street Sentiment

AMGN Performance Sentiment

Technical Price Levels

Explore our AMGN Stock insights

Receive our AMGN Daily Alerts

AMGN Street Sentiment

AMGN Risk Level

Technical Price Levels

Discover AMGN Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of AMGN. We're here to help you make informed investment decisions today.

Receive our AMGN Daily Alerts

AMGN Runner Alarm